MicroRNAs: Emerging role in the endogenous μ opioid system

CNS and Neurological Disorders - Drug Targets

Volumn 14, Issue 2, 2015, Pages 239-250

  Barbierato, Massmo ^a   Zusso, Morena ^a   Skaper, Stephen D ^a   Giusti, Pietro ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Addiction; Fentanyl; MicroRNAs; Morphine; Mu opioid receptor; Opioids; Signal transduction; Tolerance

Indexed keywords

FENTANYL; MICRORNA; MICRORNA 103; MICRORNA 107; MICRORNA 125B; MICRORNA 128; MICRORNA 133B; MICRORNA 134; MICRORNA 150; MICRORNA 155; MICRORNA 15B; MICRORNA 181B; MICRORNA 184; MICRORNA 18A; MICRORNA 190; MICRORNA 20A; MICRORNA 224; MICRORNA 23B; MICRORNA 28; MICRORNA 301; MICRORNA 339; MICRORNA 365; MICRORNA 382; MICRORNA 410; MICRORNA 602; MICRORNA LET 7; MORPHINE; MU OPIATE RECEPTOR; PROTEIN VARIANT; UNCLASSIFIED DRUG; UNINDEXED DRUG; NARCOTIC ANALGESIC AGENT;

ALTERNATIVE RNA SPLICING; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; DRUG DEPENDENCE; GENE; GENE EXPRESSION; HUMAN; HUMAN GENOME; NERVE CELL DIFFERENTIATION; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROIMMUNOLOGY; NOCICEPTION; NONHUMAN; PAIN; SEPSIS; ANIMAL; METABOLISM;

ANALGESICS, OPIOID; ANIMALS; HUMANS; MICRORNAS; RECEPTORS, OPIOID, MU;

EID: 84930914304     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527314666150116123932     Document Type: Article

References (149)

1. Chinellato A, Terrazzani G, Walley T, Giusti P. Opioids in Italy: Is marketing more powerful than the law? Lancet 2003; 362: 78-80.
2. Melnikova I. Pain market. Nat Rev Drug Discov 2010; 9: 589-90.
3. Alexander GC, Kruszewski SP, Webster DW. "Rethinking opioid prescribing to protect patient safety and public health". J Am Med Assoc 2012; 308: 1865-6.
4. Kane-Gill SL, Rubin EC, Smithburger PL, Buckley MS, Dasta JF. The cost of opioid-related adverse drug events. J Pain Palliat Care Pharmacother 2014; 28: 282-93.
5. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843-54.
6. Chen K, Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet 2007; 8: 93- 103.
7. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-33.
8. Beezhold KJ, Castranova V, Chen F. Microprocessor of microRNAs: regulation and potential for therapeutic intervention. Mol Cancer 2010; 9: 134.
9. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007; 318: 1931-4.
10. Orom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell 2008; 30: 460-71.
11. Bentwich I, Avniel A, Karov Y, et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet 2005; 37: 766-70.
12. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
13. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105.
14. Atcheson R, Lambert DG. Update on opioid receptors. Br J Anesthesiol 1994; 73: 132-4.
15. Lambert DG. Recent advances in opioid pharmacology. Br J Anesthesiol 1998; 81: 1-2.
16. Mollereau C1, Parmentier M, Mailleux P, et al. ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett 1994; 341: 33-8.
17. Mollereau C, Mouledous L. Tissue distribution of the opioid receptor-like (ORL1) receptor. Peptides 2000; 21: 907-17.
18. Chen Y, Mestek A, Liu J, Hurley JA, Yu L. Molecular cloning and functional expression of a mu-opioid receptor from rat brain. Mol Pharmacol 1993; 44: 8-12.
19. Thompson RC, Mansour A, Akil H, et al. Cloning and pharmacological characterization of a rat mu opioid receptor. Neuron 1993; 11: 903-13.
20. Wang JB, Imai Y, Eppler CM, et al. Mu opiate receptor: cDNA cloning and expression. Proc Natl Acad Sci USA 1993; 90: 10230-4.
21. Eppler CM, Hulmes JD, Wang JB, et al. Purification and partial amino acid sequence of a mu opioid receptor from rat brain. J Biol Chem 1993; 268: 26447-51.
22. Matthes HW, Maldonado R, Simonin F, et al. Loss of morphineinduced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 1996; 383: 819-23.
23. Wang JB, Johnson PS, Persico AM, Hawkins AL, Griffin CA, Uhl GR. Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. FEBS Lett 1994; 338: 217-22.
24. Shabalina SA, Zaykin DV, Gris P, et al. Expansion of the human muopioid receptor gene architecture: novel functional variants. Hum Mol Genet 2009; 18: 1037-51.
25. Min BH, Augustin LB, Felsheim RF, Fuchs JA, Loh HH. Genomic structure analysis of promoter sequence of a mouse mu opioid receptor gene. Proc Natl Acad Sci USA 1994; 91: 9081-5.
26. Giros B, Pohl M, Rochelle JM, Seldin MF. Chromosomal localization of opioid peptide and receptor genes in the mouse. Life Sci 1995; 56: PL369-75.
27. Liang Y, Mestek A, Yu L, Carr LG. Cloning and characterization of the promoter region of the mouse mu opioid receptor gene. Brain Res 1995; 679: 82-8.
28. Pan L, Xu J, Yu R, Xu MM, Pan YX, Pasternak GW. Identification and characterization of six new alternatively spliced variants of the human mu opioid receptor gene, Oprm. Neuroscience 2005; 133: 209-20.
29. Pasternak GW, Pan YX. Mu opioids and their receptors: Evolution of a concept. Pharmacol Rev 2013; 65: 1257-317.
30. Abbadie C, Pan YX, Drake CT, Pasternak GW. Comparative immunohistochemical distributions of carboxy terminus epitopes from the mu-opioid receptor splice variants MOR-1D, MOR-1 and MOR-1C in the mouse and rat CNS. Neuroscience 2000; 100: 141- 53.
31. Abbadie C, Pan YX, Pasternak GW. Differential distribution in rat brain of mu opioid receptor carboxy terminal splice variants MOR- 1C-like and MOR-1-like immunoreactivity: Evidence for regionspecific processing. J Comp Neurol 2000; 419: 244-56.
32. Pan YX, Xu A, Mahurter L, Bolan E, Xu MM, Pasternak GW. Generation of the mu opioid receptor (MOR-1) protein by three new splice variants of the Oprm gene. Proc Natl Acad Sci USA 2001; 98: 14084-9.
33. Bolan EA, Pan YX, Pasternak GW. Functional analysis of MOR-1 splice variants of the mouse mu opioid receptor gene Oprm. Synapse 2004; 51: 11-18.
34. Pan YX, Xu J, Bolan E, Moskowitz HS, Xu M, Pasternak GW. Identification of four novel exon 5 splice variants of the mouse muopioid receptor gene: functional consequences of C-terminal splicing. Mol Pharmacol 2005; 68: 866-75.
35. Koch T, Schulz S, Schroder H, Wolf R, Raulf E, Hollt V. Carboxylterminal splicing of the rat mu opioid receptor modulates agonistmediated internalization and receptor resensitization. J Biol Chem 1998; 273: 13652-7.
36. Koch T, Schulz S, Pfeiffer M, et al. C-terminal splice variants of the mouse mu-opioid receptor differ in morphine-induced internalization and receptor resensitization. J Biol Chem 2001; 276: 31408-14.
37. Tanowitz M, Hislop JN, von ZM. Alternative splicing determines the post-endocytic sorting fate of G-protein-coupled receptors. J Biol Chem 2008; 283: 35614-21.
38. Liu XY, Liu ZC, Sun YG, et al. Unidirectional cross-activation of GRPR by MOR1D uncouples itch and analgesia induced by opioids. Cell 2011; 147: 447-58.
39. Pan YX. Identification and characterization of a novel promoter of the mouse mu opioid receptor gene (Oprm) that generates eight splice variants. Gene 2002; 295: 97-108.
40. Xu J, Xu M, Pan YX. Characterizing exons 11 and 1 promoters of the mu opioid receptor (Oprm) gene in transgenic mice. BMC Mol Biol 2006; 7: 41.
41. Pan YX, Xu J, Xu M, Rossi GC, Matulonis JE, Pasternak GW. Involvement of exon 11-associated variants of the mu opioid receptor MOR-1 in heroin, but not morphine, actions. Proc Natl Acad Sci USA 2009; 106: 4917-22.
42. Majumdar S, Grinnell S, Le R, et al. Truncated G proteincoupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects. Proc Natl Acad Sci USA 2011; 108: 19778-83.
43. Majumdar S, Subrath J, Le Rouzic V, et al. Synthesis and evaluation of arylnaloxamide opiate analgesics targeting truncated exon 11- associated mu opioid receptor (MOR-1) splice variants. J Med Chem 2012; 55: 6352-62.
44. Xu J, Xu M, Brown T, et al. Stabilization of the μ-opioid receptor by truncated single transmembrane splice variants through a chaperonelike action. J Biol Chem 2013; 288: 21211-27.
45. Law PY, Wong YH, Loh HH. Molecular mechanisms and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol 2000; 40: 389-430.
46. Ferguson SS. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 2001; 53: 1-24.
47. Ahn S, Nelson CD, Garrison TR, Miller WE, Lefkowitz RJ. Desensitization, internalization, and signaling functions of betaarrestins demonstrated by RNA interference. Proc Natl Acad Sci USA 2003; 100: 1740-4.
48. Ferguson SS, Downey WE 3rd, Colapietro AM, Barak LS, Ménard L, Caron MG. Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science 1996; 271: 363-6.
49. Raehal KM, Bohn LM. β-arrestins: regulatory role and therapeutic potential in opioid and cannabinoid receptor-mediated analgesia. Handb Exp Pharmacol 2014; 219: 427-43.
50. Daaka Y, Luttrell LM, Ahn S, et al. Essential role for G proteincoupled receptor endocytosis in the activation of mitogen-activated protein kinase. J Biol Chem 1998; 273: 685-8.
51. Luttrell LM, Ferguson SS, Daaka Y, et al. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 1999; 283: 655-61.
52. McDonald PH, Chow CW, Miller WE, et al. Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science 2000; 290: 1574-7.
53. Lohse MJ, Hoffmann C. Arrestin interactions with G protein-coupled receptors. Handb Exp Pharmacol 2014; 219: 15-56.
54. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005; 122: 261-73.
55. Beaulieu JM, Marion S, Rodriguiz RM, et al. A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell 2008; 132: 125-33.
56. Schmid CL, Bohn LM. Physiological and pharmacological implications of beta-arrestin regulation. Pharmacol Ther 2009; 121: 285-93.
57. Schmid CL, Bohn LM. Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a β-arrestin2/Src/Akt signaling complex in vivo. J Neurosci 2020; 30: 13513-24.
58. Urs NM, Daigle TL, Caron MG. A dopamine D1 receptor-dependent beta-arrestin signaling complex potentially regulates morphineinduced psychomotor activation but not reward in mice. Neuropsychopharmacology 2010; 36: 551-8.
59. Kenakin T. Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther 2011; 336: 296-302.
60. Kenakin T. New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov 2005; 4: 919-27.
61. Kenakin T. Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. Trends Pharmacol Sci 2007; 28: 407-15.
62. Mailman RB. GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci 2007; 28: 390-6.
63. Urban JD, Clarke WP, von Zastrow M, et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 2007; 320: 1-13.
64. Kenakin T. Biased agonism F1000. Biol Rep 2009; 1: 87.
65. Bohn LM. Selectivity for G protein or arrestin-mediated signaling. In: Neve K, Ed. Functional selectivity of G protein-coupled receptor ligands. 1st ed. Totowa: Humana Press 2009; pp. 71-85.
66. Schmid CL, Bohn LM. Physiological and pharmacological implications of beta-arrestin regulation. Pharmacol Ther 2009; 121: 285-93.
67. Cox BM. Recent developments in the study of opioid receptors. Mol Pharmacol 2013; 83: 723-8.
68. Cui X, Yeliseev A, Liu R. Ligand interaction, binding site and G protein activation of the mu opioid receptor. Eur J Pharmacol 2013; 702: 309-15.
69. Jeal W, Benfield P. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997; 53: 109-38.
70. Pergolizzi J, Böger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008; 8: 287-313.
71. Duttaroy A, Yoburn BC. The effect of intrinsic efficacy on opioid tolerance. Anesthesiology 1995; 82: 1226-36.
72. Zheng H, Zeng Y, Zhang X, Chu J, Loh HH, Law PY. μ-Opioid receptor agonists differentially regulate the expression of miR-190 and NeuroD. Mol Pharmacol 2010; 77: 102-9.
73. Zheng H, Chu J, Zeng Y, Loh HH, Law PY. Yin Yang 1 phosphorylation contributes to the differential effects of mu-opioid receptor agonists on microRNA-190 expression. J Biol Chem 2010; 285: 21994-2002.
74. Yang Y, Zhi F, He X, et al. δ-opioid receptor activation and microRNA expression of the rat cortex in hypoxia. PLoS One 2012; 7: 12.
75. He X, Yang Y, Zhi F, et al. δ-Opioid receptor activation modified microRNA expression in the rat kidney under prolonged hypoxia. PLoS One 2013; 8:4.
76. Wu Q, Law PY, Wei LN, Loh HH. Post-transcriptional regulation of mouse mu opioid receptor (MOR1) via its 3′ untranslated region: a role for microRNA23b. FASEB J 2008; 22: 4085-95.
77. Wu Q, Zhang L, Law PY, Wei LN, Loh HH. Long-term morphine treatment decreases the association of mu-opioid receptor (MOR1) mRNA with polysomes through miRNA23b. Mol Pharmacol 2009; 75: 744-750.
78. Sanchez-Simon FM, Zhang XX, Loh HH, Law PY, Rodriguez RE. Morphine regulates dopaminergic neuron differentiation via miR- 133b. Mol Pharmacol 2010; 78: 935-42.
79. Dave RS, Khalili K. Morphine treatment of human monocyte-derived macrophages induces differential miRNA and protein expression: impact on inflammation and oxidative stress in the central nervous system. J Cell Biochem 2010; 110: 834-45.
80. He Y, Yang C, Kirkmire CM, Wang ZJ. Regulation of opioid tolerance by let-7 family microRNA targeting the mu opioid receptor. J Neurosci 2010; 30: 10251-8.
81. Lu Z, Xu J, Xu M, Pasternak GW, Pan YX. Morphine regulates expression of μ-opioid receptor MOR-1A, an intron-retention carboxyl terminal splice variant of the μ-opioid receptor (OPRM1) gene via miR-103/miR-107. Mol Pharmacol 2014; 85: 368-80.
82. Wu Q, Hwang CK, Zheng H, et al. MicroRNA 339 down-regulates μ-opioid receptor at the post-transcriptional level in response to opioid treatment. FASEB J 2013; 27: 522-35.
83. Gonzalez-Nunez V, Noriega-Prieto JA, Rodríguez RE. Morphine modulates cell proliferation through mir133b &mir128 in the neuroblastoma SH-SY5Y cell line. Biochim Biophys Acta 2014; 1842: 566-72.
84. Ide S, Han W, Kasai S, Hata H, Sora I, Ikeda K. Characterization of the 3' untranslated region of the human mu-opioid receptor (MOR-1) mRNA. Gene 2005; 364: 139-45.
85. Han W, Kasai S, Hata H, et al. Intracisternal A-particle element in the 3' noncoding region of the mu-opioid receptor gene in CXBK mice: a new genetic mechanism underlying differences in opioid sensitivity. Pharmacogenet Genom 2006; 16: 451-60.
86. Zöllner C, Johnson PS, Bei Wang J, et al. Control of mu opioid receptor expression by modification of cDNA 5'- and 3'-noncoding regions. Brain Res Mol Brain Res 2000; 79: 159-62.
87. Levis M, Murphy KM, Pham R, et al. Internal tandem duplications of the FLT3 gene are present in leukemia stem cells. Blood 2005; 106: 673-80.
88. Liu NK, Wang XF, Lu QB, Xu XM. Altered microRNA expression following traumatic spinal cord injury. Exp Neurol 2009; 219: 424-9.
89. Ni J, Gao Y, Gong S, Guo S, Hisamitsu T, Jiang X. Regulation of μ- opioid type 1 receptors by microRNA134 in dorsal root ganglion neurons following peripheral inflammation. Eur J Pain 2013; 17: 313- 23.
90. Robinson TE, Berridge KC. Addiction. Annu Rev Psychol 2003; 54: 25-53.
91. Chao J, Nestler EJ. Molecular neurobiology of drug addiction. Annu Rev Med 2004; 55: 113-32.
92. Eisch AJ, Harburg GC. Opiates, psychostimulants, and adult hippocampal neurogenesis: insights for addiction and stem cell biology. Hippocampus 2006; 16: 271-86.
93. Kempermann G, Jessberger S, Steiner B, Kronenberg G. Milestones of neuronal development in the adult hippocampus. Trends Neurosci 2004; 27: 447-52.
94. Zheng H, Zhang Y, Li W, Loh HH, Law PY. NeuroD modulates opioid agonist-selective regulation of adult neurogenesis and contextual memory extinction. Neuropsychopharmacology 2013; 38: 770-7.
95. Rodriguez RE. Morphine and microRNA Activity: Is there a relation with addiction? Front Genet 2012; 3: 223.
96. Neves G, Cooke SF, Bliss TV. Synaptic plasticity, memory and the hippocampus: a neural network approach to causality. Nat Rev Neurosci 2008; 9: 65-75.
97. Restivo L, Vetere G, Bontempi B, Ammassari-Teule M. The formation of recent and remote memory is associated with timedependent formation of dendritic spines in the hippocampus and anterior cingulate cortex. J Neurosci 2009; 29: 8206-14.
98. Fan GH, Wang LZ, Qiu HC, Ma L, Pei G. Inhibition of calcium/calmodulin-dependent protein kinase II in rat hippocampus attenuates morphine tolerance and dependence. Mol Pharmacol 1999; 56: 39-45.
99. Milekic MH, Brown SD, Castellini C, Alberini CM. Persistent disruption of an established morphine conditioned place preference. J Neurosci 2006; 26: 3010-20.
100. Chen Y, Jiang Y, Yue W, Zhou Y, Lu L, Ma L. Chronic, but not acute morphine treatment, up-regulates alpha-Ca2+/calmodulin dependent protein kinase II gene expression in rat brain. Neurochem Res 2008; 33: 2092-8.
101. Seo S, Lim JW, Yellajoshyula D, Chang LW, Kroll KL. Neurogenin and NeuroD direct transcriptional targets and their regulatory enhancers. EMBO J 2007; 26: 5093-108.
102. Zheng H, Zeng Y, Chu J, Kam AY, Loh HH, Law PY. Modulations of NeuroD activity contribute to the differential effects of morphine and fentanyl on dendritic spine stability. J Neurosci 2010; 30: 8102- 10.
103. Kim E, Clark AL, Kiss A, et al. Mu- and kappa-opioids induce the differentiation of embryonic stem cells to neural progenitors. J Biol Chem 2006; 281: 33749-60.
104. Macey TA, Bobeck EN, Hegarty DM, Aicher SA, Ingram SL, Morgan MM. Extracellular signal-regulated kinase 1/2 activation counteracts morphine tolerance in the periaqueductal gray of the rat. J Pharmacol Exp Ther 2009; 331: 412-8.
105. Hollander JA, Im HI, Amelio AL, et al. Striatal microRNA controls cocaine intake through CREB signalling. Nature 2010; 466: 197-202.
106. Dreyer JL. New insights into the roles of microRNAs in drug addiction and neuroplasticity. Genome Med 2010; 2: 92.
107. Schaefer A, Im HI, Venø MT, et al. Argonaute 2 in dopamine 2 receptor-expressing neurons regulates cocaine addiction. J Exp Med 2010; 207: 1843-51.
108. Wang X, Ye L, Zhou Y, Liu MQ, Zhou DJ, Ho WZ. Inhibition of anti-HIV microRNA expression: a mechanism for opioid-mediated enhancement of HIV infection of monocytes. Am J Pathol 2011; 178: 41-7.
109. Bell JE, Arango JC, Anthony IC. Neurobiology of multiple insults: HIV-1-associated brain disorders in those who use illicit drugs. J Neuroimmune Pharmacol 2006; 1: 182-91.
110. Fitting S, Xu R, Bull C, et al. Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons. Am J Pathol 2010; 177: 1397-410.
111. Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol 2005; 5: 69-81.
112. Hauser KF, El-Hage N, Stiene-Martin A, et al. HIV-1 neuropathogenesis: glial mechanisms revealed through substance abuse. J Neurochem 2007; 100: 567-86.
113. Schwartz C, Catez P, Rohr O, Lecestre D, Aunis D, Schaeffer E. Functional interactions between C/EBP, Sp1, and COUP-TF regulate human immunodeficiency virus type 1 gene transcription in human brain cells. J Virol 2000; 74: 65-73.
114. Wang J, Gabuzda D. Reconstitution of human immunodeficiency virus-induced neurodegeneration using isolated populations of human neurons, astrocytes, and microglia and neuroprotection mediated by insulin-like growth factors. J Neurovirol 2006; 12: 472-91.
115. Wang X, Ye L, Hou W, et al. Cellular microRNA expression correlates with susceptibility of monocytes/macrophages to HIV-1 infection. Blood 2009; 113: 671-4.
116. Perry AK, Chen G, Zheng D, Tang H, Cheng G. The host type I interferon response to viral and bacterial infections. Cell Res 2005; 15: 407-22.
117. Mogensen TH, Melchjorsen J, Larsen CS, Paludan SR. Innate immune recognition and activation during HIV infection. Retrovirology 2010; 7: 54.
118. O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA 2007; 104: 1604-9.
119. Pedersen IM, Cheng G, Wieland S, et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 2007; 449: 919-22.
120. Ohno M, Natsume A, Kondo Y, et al. The modulation of microRNAs by type I IFN through the activation of signal transducers and activators of transcription 3 in human glioma. Mol Cancer Res 2009; 7: 2022-30.
121. Nair MP, Schwartz SA, Polasani R, Hou J, Sweet A, Chadha KC. Immunoregulatory effects of morphine on human lymphocytes. Clin Diagn Lab Immunol 1997; 4: 127-32.
122. Homan JW, Steele AD, Martinand-Mari C, et al. Inhibition of morphine-potentiated HIV-1 replication in peripheral blood mononuclear cells with the nuclease-resistant 2-5A agonist analog, 2- 5A(N6B). J Acquir Immune Defic Syndr 2002; 30: 9-20.
123. Donahoe RM, Vlahov D. Opiates as potential cofactors in progression of HIV-1 infections to AIDS. J Neuroimmunol 1998; 83: 77-87.
124. Vallejo R, de Leon-Casasola O, Benyamin R. Opioid therapy and immunosuppression: a review. Am J Ther 2004; 11: 354-65.
125. Tuttle DL, Harrison JK, Anders C, Sleasman JW, Goodenow MM. Expression of CCR5 increases during monocyte differentiation and directly mediates macrophage susceptibility to infection by human immunodeficiency virus type 1. J Virol 1998; 72: 4962-9.
126. Gottlieb GS, Heath L, Nickle DC, et al. HIV-1 variation before seroconversion in men who have sex with men: analysis of acute/early HIV infection in the multicenter AIDS cohort study. J Infect Dis 2008; 197: 1011-5.
127. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008; 105: 7552- 7.
128. Guo CJ, Li Y, Tian S, Wang X, Douglas SD, Ho WZ. Morphine enhances HIV infection of human blood mononuclear phagocytes through modulation of beta-chemokines and CCR5 receptor. J Investig Med 2002; 50: 435-42.
129. Li Y, Wang X, Tian S, Guo CJ, Douglas SD, Ho WZ. Methadone enhances human immunodeficiency virus infection of human immune cells. J Infect Dis 2002; 185: 118-22.
130. Ho WZ, Guo CJ, Yuan CS, Douglas SD, Moss J. Methylnaltrexone antagonizes opioid-mediated enhancement of HIV infection of human blood mononuclear phagocytes. J Pharmacol Exp Ther 2003; 307: 1158-62.
131. Jeffrey GP, MacQuillan G, Chua F, et al. Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants. Hepatology 2007; 45: 111-7.
132. Roy S, Ninkovic J, Banerjee S, et al. Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections. J Neuroimmune Pharmacol 2011; 6: 442-65.
133. Ma J, Wang J, Wan J, et al. Morphine disrupts interleukin-23 (IL- 23)/IL-17-mediated pulmonary mucosal host defense against Streptococcus pneumoniae infection. Infect Immun 2010; 78: 830-7.
134. Breslow JM, Feng P, Meissler JJ, et al. Potentiating effect of morphine on oral Salmonella enterica serovar Typhimurium infection is μ-opioid receptor-dependent. Microb Pathog 2010; 49: 330-5.
135. Runkel NS, Moody FG, Smith GS, et al. Alterations in rat intestinal transit by morphine promote bacterial translocation. Dig Dis Sci 1993; 38: 1530-6.
136. Babrowski T, Holbrook C, Moss J, et al. Pseudomonas aeruginosa virulence expression is directly activated by morphine and is capable of causing lethal gut-derived sepsis in mice during chronic morphine administration. Ann Surg 2012; 255: 386-93.
137. Xiong J, Miller VM, Hunter LW, Li Y, Jayachandran M. Leukocyteand platelet-derived microvesicle interactions following in vitro and in vivo activation of toll-like receptor 4 by lipopolysaccharide. PLoS One 2011; 6(9):e25504.
138. Banerjee S, Meng J, Das S, et al. Morphine induced exacerbation of sepsis is mediated by tempering endotoxin tolerance through modulation of miR-146a. Sci Rep 2013; 3: 1977.
139. Rasmussen M, Zhu W, Tønnesen J, Cadet P, Tønnesen E, Stefano GB. Effects of morphine on tumour growth. Neuro Endocrinol Lett 2002; 23: 193-8.
140. Sun E, Shi Y. MicroRNAs: Small molecules with big roles in neurodevelopment and diseases. Exp Neurol 2014; pii: S0014- 4886(14)00257-X.
141. Aksoy-Aksel A, Zampa F, Schratt G. MicroRNAs and synaptic plasticity--a mutual relationship. Philos Trans R Soc Lond B Biol Sci 2014; 369(1652): pii: 20130515.
142. Maciotta S, Meregalli M, Torrente Y. The involvement of microRNAs in neurodegenerative diseases. Front Cell Neurosci 2013; 7: 265.
143. Otsuka K, Ochiya T. Genetic networks lead and follow tumor development: microRNA regulation of cell cycle and apoptosis in the p53 pathways. Biomed Res Int 2014; 2014: 749724.
144. Siepel A, Haussler D. Combining phylogenetic and hidden Markov models in biosequence analysis. J Comput Biol 2004; 11: 413-28.
145. Siepel A, Bejerano G, Pedersen JS, et al. Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res 2005; 15: 1034-50.
146. Hwang CK, Wagley Y, Law PY, Wei LN, Loh HH. MicroRNAs in opioid pharmacology. J Neuroimmune Pharmacol 2012; 7: 808-19.
147. Choi HS, Kim CS, Hwang CK, et al. The opioid ligand binding of human mu-opioid receptor is modulated by novel splice variants of the receptor. Biochem Biophys Res Commun 2006; 19: 1132-40.
148. Xu J, Xu M, Hurd YL, Pasternak GW, and Pan YX. Isolation and characterization of new exon 11-associated N-terminal splice variants of the human mu opioid receptor gene. J Neurochem 2009; 108: 962- 72.
149. Andersen A, Baar C, Fladvad T, Laugsand EA, and Skorpen F. The N-terminally truncated μ3 and μ3-like opioid receptors are transcribed from a novel promoter upstream of exon 2 in the human OPRM1 gene. Plos One 2013; 8: e71024.